Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
HOME > COMMENTARY
COMMENTARY
- Tougher Pricing Policy, New Products Essential to Offset Impact of NHI Price Revision
March 27, 2006
- No Domestic Company Moves Despite Expected Growth: Vaccine Business
March 27, 2006
- FY2006 NHI Price Revision: Industry Succeeds in Defensive Efforts
March 13, 2006
- Effects of Medical Fee Revision Need to be Verified
March 6, 2006
- Pfizer Management, Labor See Signs of Snowbreak
March 6, 2006
- ＜COMMENTARY＞ New Dispensing Fees Nearly Decided
February 20, 2006
- Japan's Most Admired Pharma Companies P. Reed Maurer
February 20, 2006
- Frustrating Outcome for Industry: Exceptional NHI Price Reduction for Long-listed Drugs
February 13, 2006
- Requirements for External IRBs to Be Relaxed
February 13, 2006
- Astellas' Inventorship Issue with Professor Ochiai - What If This Were a US Case?
February 6, 2006
- COMMENTARY 2 articles
January 30, 2006
- JPLA SEMINAR
January 30, 2006
- Maurer's Healthcare Insight (72)
January 30, 2006
- Astellas' Inventorship Issue with Professor Ochiai - What If This Were a US Case?
January 30, 2006
- Vascular Calcification: Ultimate Consequnce of Vascular Atherosclerosis (II) -2-
January 30, 2006
- Vascular Calcification: Ultimate Consequnce of Vascular Atherosclerosis (II) -1-
January 30, 2006
- From "Replacement" to "Addition": Prescription Form
January 23, 2006
- Vascular Calcification: Ultimate Consequnce of Vascular Atherosclerosis (I) －２－
January 23, 2006
- Vascular Calcification: Ultimate Consequnce of Vascular Atherosclerosis (I) －１－
January 23, 2006
- A Happy Year 2006 to Japanese Pharmaceutical Stocks!
January 23, 2006
ページ
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…